anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of biological medicines, and discloses a polypeptide with antibacterial and osteogenic activities, a preparation and application thereof. The invention designs a polypeptide with antibacterial and osteogenic activities, and the amino acid sequence of the polypeptide is shown as any one sequence of SEQ ID No.1, SEQ ID No.2 and SEQ ID No. 3. The invention provides a preparation containing the polypeptide or the derivative of the polypeptide, and the application of the polypeptide and the preparation in preparing medicines for treating jawbone infection or maxillofacial infectious bone defects. The polypeptide has small molecules and good effect of resisting maxillofacial infectious bone defect related bacteria; the biological safety is good, and the bone potential is good; good activity, low concentration of active ingredients, good effect and low cost required by clinical application. The invention solves the antibacterial problem and regeneration promoting problem of maxillofacial infectious bone defect at the same time, and has new design concept and good clinical application potential.
FIELD: medicine. SUBSTANCE: innovation deals with detergent products for hygienic purposes, predominantly for conditions of increased radioactive contamination and could be used for deactivation of hairy and body skin coverings, for deactivation of linen at washing at the stage of rinsing and, also, for deactivation of different surfaces. The detergent contains trilon B and water, additionally, whey, ascorbic or citric, or salicylic acids at the following ratio of components, wt.%: whey, 3.0-6.0; ascorbic or citric, or salicylic acid, 0.1-0.5; trilon B, 0.1-0.5; water, the balance. Moreover, the product may contain, additionally, a humate, mineral acid, glycols and surface- active substances. The product provides complex detergent and deactivating properties being efficient in deactivation of not easily accessible places. EFFECT: higher efficiency. 5 cl, 2 tbl
INTRODUCTION: Fatigue is a prominent symptom in post-COVID condition (PCC) sequelae, termed "long COVID." Herein, we aim to ascertain the effect of fatigue on psychosocial function in persons living with PCC.
METHODS: This post hoc analysis evaluated the effects of vortioxetine on measures of fatigue as assessed by the Fatigue Severity Scale (FSS) in psychosocial function as measured by the Sheehan Disability Scale (SDS) in persons with PCC. We also evaluated the change in FSS on psychosocial functioning as measured by the Sheehan Disability Scale (SDS). This post hoc analysis obtained data from a recently published placebo-controlled study evaluating vortioxetine's effect on objective cognitive functions in persons living with PCC.
RESULTS: One hundred forty-four participants meeting World Health Organization (WHO) criteria for PCC were included in this analysis. At the end of 8 weeks of vortioxetine treatment, significant improvement of all domains was observed for psychosocial functioning. There was a significant between-group difference at treatment endpoint in the family, social, and work SDS subcategories (p < 0.001). There was a statistically significant interaction effect between the treatment condition time point and FSS effect on the SDS social (χ2 = 10.640, p = 0.014) and work (χ2 = 9.342, p = 0.025) categories but a statistically insignificant effect on the family categories ((χ2 = 5.201, p = 0.158)).
DISCUSSION: This post hoc analysis suggests that vortioxetine treatment significantly improves psychosocial function in persons with PCC. Our results also indicate that the improvement in psychosocial function was significantly mediated by improvement in measures of fatigue. Our results provide empirical support for recommendations to identify therapeutics for fatigue in persons living with PCC with a broader aim to improve psychosocial function in this common and severely impaired population.
INTRODUCTION: Acute mastoiditis is a serious condition that carries with it a high rate of morbidity and mortality.
OBJECTIVE: This review highlights the pearls and pitfalls of mastoiditis, including the presentation, diagnosis, and management in the emergency department (ED) based on current evidence.
DISCUSSION: Acute mastoiditis most commonly affects pediatric patients and is a suppurative infection of the mastoid air cells. It is often associated with otitis media, and common bacteria include Streptococcus and Staphylococcus. History and examination may reveal tympanic membrane erythema, pinna protrusion, postauricular erythema, mastoid tenderness with palpation, external canal swelling, otorrhea, fever, and malaise. The disease should be suspected in those who fail treatment for otitis media and those who demonstrate the aforementioned abnormalities on examination and systemic symptoms. Laboratory analysis may reveal evidence of systemic inflammation, but a normal white blood cell count and other inflammatory markers should not be used to exclude the diagnosis. Computed tomography (CT) of the temporal bones with intravenous contrast is the recommended imaging modality if the clinician is unsure of the diagnosis. CT may also demonstrate complications. Treatment includes antibiotics such as ampicillin-sulbactam or ceftriaxone as well as otolaryngology consultation. Complications may include subperiosteal and intracranial abscess, deep neck abscess, facial nerve palsy, meningitis/encephalitis, venous sinus thrombosis, and seizures.
CONCLUSIONS: An understanding of acute mastoiditis can assist emergency clinicians in diagnosing and managing this potentially deadly disease.
A 71-year-old male who suffered from Hoehn and Yahr stage III Parkinson's disease with bradykinesia, rigidity and a 5-6-Hz tremor at rest in the right extremities was admitted to our hospital due to the sudden onset of vertigo. Right cerebellar hemorrhage was confirmed by CT. The patient's resting tremor in the right extremities disappeared immediately following the cerebellar hemorrhage. Six days later, MRI showed Wallerian degeneration in the cerebello-rubro-thalamic tract. Approximately 5 months later, a 2-3-Hz Holmes' tremor gradually appeared in the right upper extremity. This tremor was improved by increasing L-dopa doses. Case reports of the disappearance of Parkinson's resting tremor and subsequent emergence of Holmes' tremor due to cerebellar lesion are rare. Furthermore, the Wallerian degeneration of the cerebello-rubro-thalamic tract identified on MRI between tremors of the different frequencies is very rare. We hypothesize that the cause of the tremor frequency change was simultaneous damage to the nigro-striatal network and the cerebello-thalamo-cerebral network.
PURPOSE:To obtain a highly active catalyst without requiring complicated operation for ultra-fine pulverization even when gold is used as an active seed by using a support coated with gold or a fine gold particle as a carrier and supporting transition metal oxide on the surface of the carrier in a dispersed state. CONSTITUTION:As a carrier supporting metal oxide, a fine gold particle or a support coated with gold is used. A soluble or insoluble compound of gold is dissolved or dispersed in water as a gold precursor and a soluble salt of a transition metal component to be supported is added to this aqueous solution or dispersion. The aqueous solution or dispersion is evaporated and the evaporation residue is baked in air. By this operation, the soluble or insoluble compound of gold is changed to a stable metal state and the hydroxide or water-soluble salt of the transition metal component supported on the surface of the gold particle or the gold coated support is changed to an oxide form. By this method, a gold-oxide composite is obtained without ultra-finely dividing gold and extremely useful as a catalyst having high catalytic activity.
PURPOSE OF REVIEW: To review the evidence and role of monosodium glutamate (MSG) as a headache and migraine trigger.
RECENT FINDINGS: MSG is a common food additive, has widely been linked as a trigger of headache, as well as other symptoms. However, the evidence for MSG as a causative agent for headache is debated. Various clinical trials over the past several decades have reported conflicting results, with studies suggesting that MSG does and does not increase the incidence of headache. However, the dosages of MSG exposure are often inconsistent across studies, with many studies administering a dose significantly higher than the average consumption.. Additionally, there are misconceptions about which foods and cuisines have MSG in them. MSG could be a potential trigger for migraine and headaches. It is unclear exactly how MSG plays into the migraine pathophysiology. It's crucial to accurately determine if MSG is present in one's diet to evaluate its potential impact on headaches.
The invention consists of recombinant gene expression vectors and vaccines useful in immunization of a host against an antigen and methods for use of such vectors and vaccines. In particular, the recombinant gene expression vectors of the invention are plasmids, cosmids or viruses which include non-coding, palindromic regions of single or double-stranded DNA or RNA polynucleotides which include at least one cytosine-guanine dinucleotide motif in each palindrome. These polynucleotide regions of each expression vector are immunostimulatory and serve as adjuvants to vaccination protocols against target antigens. Most preferably, the recombinant gene expression vectors of the invention are naked; i.e., non-viral vectors not associated with a delivery vehicle such as a liposome. The invention also includes live viral vaccines wherein the viruses include immunostimulatory polynucleotides of the invention. According to a preferred method of the invention, a target protein antigen is administered through its expression by a recombinant gene expression vector which contains the non-coding, immunostimulatory polynucleotides of the invention. In the most preferred embodiment of the method of the invention, the recombinant gene expression vector is administered to a tissues of the host which contain a relatively high concentration of antigen presenting cells (e.g., skin or mucosa) compared to other host tissues.
INTRODUCTION: Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.
AREAS COVERED: Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy.
EXPERT OPINION: Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.
PURPOSE:To simplify an operation with high accuracy by using an insolubilized antigen formed by immobilizing at least one kind of synthetic peptides in the components of the constituting protein of leukemia virus to an insoluble carrier. CONSTITUTION:The peptides in the components of the constituting protein of the leukemia virus are synthesized in accordance with the amino acid configuration predicted in accordance with the nucleic acid configuration of the gag (core) gene and env (envelope) gene of virus I type. The peptides which are subjected to purity calibration and with which a single peak is admitted are used. The immobilization thereof to the insoluble carrier, i.e. the prepn. of the insolubilized antigen is executed by contact in a physical adsorption method and by conjugation using a crosslinking agent in a chemical conjugation method. The antigen-antibody reactant formed by the antigen-antibody reaction of this insolubilized antigen and the antibody associated with leukemia is labeled and the labeled activity thereof is measured.
BACKGROUND: Klebsiella pneumoniae invasive syndrome (KPIS) is characterized by primary pyogenic liver abscess associated with metastatic infections. Although rare, Klebsiella endocarditis carries a high mortality risk.
CASE PRESENTATION: A 60-year-old lady with type II diabetes mellitus presented with fever, malaise, right hypochondriac pain and vomiting for two weeks. Ultrasound abdomen revealed a collection within liver, and distended gallbladder with echogenic debris within. 3 days after ultrasound guided pigtail drainage of gallbladder empyema, newly presence murmur detected. Pus, urine, and blood cultures obtained were positive for Klebsiella pneumonia. Echocardiogram exhibited oscillating mass attached to anterior mitral valve leaflet. After 6 weeks of intravenous ceftriaxone, follow-up echocardiogram and ultrasound showed complete resolution of mitral valve vegetation, hepatic and gallbladder collection.
CONCLUSION: Concomitant extrahepatic infective endocarditis (IE) should raise concerns in daily practice for patients with Klebsiella pneumoniae liver abscesses, despite the rarity of Klebsiella endocarditis. In the absence of diagnostic suspicion, antibiotic treatment regimens may be shortened, and adverse effects from IE infection may ensue.
The experimental group received AD16, which was a tablet with a dosage form of 10mg/tablet. Take warm water orally on an empty stomach in the morning, once a day.7 dosing cohorts will receive a single oral dose of AD16.
PROBLEM TO BE SOLVED: To obtain a beautifully whitening agent containing a specific essential oil ingredient as an active ingredient and exhibiting a melamine production- inhibiting effect without affecting human skin cells. SOLUTION: This beautifully withering agent contains thymol and/or carvacrol obtained by purifying an essential oil component such as thyme oil as an active ingredient. The thyme oil is an essential oil component extracted from thyme having been used as a spice. The thymol is contained in the thyme oil in an amount of approximately 60%. The carvacrol is an isomer of the thymol. The thymol and the carvacrol have tyrosinase-inhibiting activities and melamine production-inhibiting activities, respectively. Not only the thymol and the carvacrol but also the essential oil component containing the thymol and the carvacrol may be used as the active ingredient. The beautifully whitening agent preferably contains the active ingredient in an amount of approximately 0.01-20wt.%.
Peptidoglycan recognition protein 1 (PGLYRP1) is a pattern-recognition protein that mediates antibacterial actions and innate immune responses. Its expression and role in neuroinflammatory conditions remain unclear. We observed the upregulation of PGLYRP1 in inflamed human and mouse spinal cord and brain, with microglia being the primary cellular source. Experiments using a recombinant PGLYRP1 protein show that PGLYRP1 potentiates reactive gliosis, neuroinflammation, and consequent behavioral changes in multiple animal models of neuroinflammation. Furthermore, shRNA-mediated knockdown of Pglyrp1 gene expression attenuates this inflammatory response. In addition, we identify triggering receptor expressed on myeloid cell-1 (TREM1) as an interaction partner of PGLYRP1 and demonstrate that PGLYRP1 promotes neuroinflammation through the TREM1-Syk-Erk1/2-Stat3 axis in cultured glial cells. Taken together, our results reveal a role for microglial PGLYRP1 as a neuroinflammation mediator. Finally, we propose that PGLYRP1 is a potential biomarker and therapeutic target in various neuroinflammatory diseases.
Prevention strategies that aim to test and treat people for HIV infection are undermined by HIV treatment non-adherence and sexually transmitted co-infections (STI). Scalable interventions are urgently needed to sustain low infectiousness by improving HIV treatment adherence and reducing risks for transmitting HIV. This application proposes to test a theory-based behavioral intervention to simultaneously improve HIV treatment adherence and reduce HIV transmission risk behaviors in people living with HIV/AIDS who use alcohol and other drugs. Grounded in Conflict Theory of Decision Making, the intervention will be delivered in a mixed format, with one office-based counseling session followed by four cell phone delivered counseling sessions. The intervention will be conducted in Atlanta and surrounding impoverished areas. Men (n = 250) and women (n = 250) receiving HIV treatment will be recruited from AIDS services and infectious disease clinics. Following informed consent and baseline assessments, participants will be randomly assigned to either an (a) integrated HIV treatment adherence - risk reduction intervention or (b) a time-matched non-contaminating attention control condition. Participants will be followed for 12-months using office-based computerized interviews, unannounced pill counts, and medical chart abstraction. The study will test the hypothesis that a unified, integrated theory-based HIV treatment and risk reduction intervention will reduce HIV transmission risk behaviors, improve HIV treatment adherence, reduce viral load and prevent new STI. The study will also examine the influence of theoretical constructs and structural barriers on intervention outcomes. Factors that predict relapse to non-adherence and risk behaviors in relation to changes in viral load and STI over the 12-month follow-up period will also be a focal point of the study. The intervention under investigation will be among the first to simultaneously address treatment adherence and risk behavior in an integrated model for substance using HIV positive men and women. If shown effective, the intervention model will be ready for immediate dissemination to community and clinical services for people living with HIV/AIDS.
Solutions with osmolarity of 900 mOsm/L or greater must be infused through a central catheter. CLINIMIX E solutions containing more than 5% dextrose have an osmolarity greater than or equal to 900 mOsm/L. CLINIMIX E 4.25/10, 5/15, 5/20, 8/10 and 8/14 are indicated for administration into a central vein only, such as the superior vena cava [see Dosage and Administration (2.2)]. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis.

CLINIMIX E 2.75/5 and 4.25/5 are indicated for peripheral administration, or may be infused into a central vein [see Dosage and Administration (2.2)]. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.
Teens will participate in BA-A. BA-A is a 12-session manualized treatment that utilizes established BA strategies and incorporates common mental health treatment adaptations for young people with ASD.
The control group will receive a similar 2-session brief motivational intervention. Session 1 focuses on nutrition and healthy eating, session 2 focuses on exercising while pregnant or in the postpartum period.
PURPOSE:A low-toxicity immunoregulator that contains cyanocobalamin as an active ingredient, thus showing effect in prevention and remedy for infections and malignant tumors. CONSTITUTION:The objective immunoregulator contains cyanocobalamin (vitamin B12; 5,6-dimethylbenzimidazolyl cyanocobalmide) as an active ingredients. It recovers the suppressed immunity or strengthens the normal immunity to increase the resistance to the proliferation of pathogenic microorganisms such as bacteria or viruses in vivo and to malignant tumors. In the meantime, the abnormally stimulated immune reaction is controlled and the regulator also is applicable to autoimmune diseases such as allergic diseases. It can be given orally or parenterally and the dose to an adult is 100g-10mg every dosage and it is given once or more a day. It can be combined with another antitumor agent, antibiotic or antiinflammatory.
PURPOSE:To obtain a melanization inhibitory drug for external use capable of producing synergistic inhibitory effects on pigmentation by using kojic acid or an ester thereof and an extract of malt roots in combination. CONSTITUTION:A melanization inhibitory drug for external use is obtained by using 0.1-5wt.% kojic acid or an ester thereof and 0.5-10wt.% extract of malt roots in combination. The aforementioned melanization inhibitory drug has synergistically enhanced melanization inhibitory effects. The malt roots are root parts of malts utilized for producing thick malt syrup and brewing beer utilizing hydrolysis of starch and have hitherto been disposed of. For example, cosmetics such as cream, toilet water, pack and powder or further medicines or quasi-drugs such as milky lotion, lotion, liniment and ointment are cited as the drug for external use. The above-mentioned drug for external use is extremely useful for preventing and treating pigmentation such as chloasma by application thereof to affects parts.
Lomentospora prolificans is an uncommon cause of invasive fungal disease, but it is associated with high mortality because it is difficult to treat. Most of severe cases are produced in immunossupressed patients, especially in those with neutropenia and/or hematological malignancies. Resistance to the majority of antifungal agents can be still observed. Here we report two cases of L. prolificans fungemia with different outcome, since in one of these patients treatment with one of the new antifungals could be applied. Both patients were treated with different antifungal drugs, but only the second one survived due to therapy with fosmanogepix®. The current treatment is still based on a combination of conventional antifungal drugs, although in much cases this strategy is not sufficient. The introduction of new promising antifungal agents such as fosmanogepix® and olorofim® may open new perspectives in the treatment of invasive infections caused by L. prolificans, as in our patient.
Disclosed is a risk evaluation system that uses people as sensors, wherein a control unit (21) in a stress management system (20) obtains mental health information and records same in a measurement information database (25). The control unit (21) then specifies a pattern in a reference pattern database (24) and obtains the measurement information relating to this pattern from the measurement information database (25). The control unit (21) in the stress management system (20) then revises a standard pattern based on individual attributes or work attributes. Next, the control unit (21) performs pattern matching and determines whether or not attention is required. If the determination is that attention is required, the control unit (21) presents an alert and an advice. This enables work, organization, and member risks to be appropriately evaluated based on changes in mental health information for a user.